Actuate Therapeutics, Inc. Common stock
NGM: ACTULive Quote
About Actuate Therapeutics, Inc. Common stock
Healthcare
Biotechnology
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
📊 Fundamental Analysis
Actuate Therapeutics, Inc. Common stock demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -553.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.72, ACTU currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $1.69 - $11.99).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
Key Financials
Market Cap
$48.09M
Trailing P/E
--
Forward P/E
-1.71
Beta (5Y)
--
52W High
$11.99
52W Low
$1.69
Avg Volume
74K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App